AT434438T - Combination comprising an inhibitor of the signal transduction and an epothilone derivative - Google Patents

Combination comprising an inhibitor of the signal transduction and an epothilone derivative

Info

Publication number
AT434438T
AT434438T AT02744903T AT02744903T AT434438T AT 434438 T AT434438 T AT 434438T AT 02744903 T AT02744903 T AT 02744903T AT 02744903 T AT02744903 T AT 02744903T AT 434438 T AT434438 T AT 434438T
Authority
AT
Austria
Prior art keywords
inhibitor
combination
signal transduction
epothilone derivative
epothilone
Prior art date
Application number
AT02744903T
Other languages
German (de)
Inventor
Elisabeth Buchdunger
Carl-Henrik Heldin
Arne Oestman
Kristian Pietras
Terence O'reilly
John Rothermel
Peter Traxler
Markus Wartmann
Ralf Brandt
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB0104840A priority Critical patent/GB0104840D0/en
Priority to US33904001P priority
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Priority to PCT/EP2002/002049 priority patent/WO2002067941A2/en
Publication of AT434438T publication Critical patent/AT434438T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
AT02744903T 2001-02-27 2002-02-26 Combination comprising an inhibitor of the signal transduction and an epothilone derivative AT434438T (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB0104840A GB0104840D0 (en) 2001-02-27 2001-02-27 Use of organic compounds
US33904001P true 2001-10-30 2001-10-30
PCT/EP2002/002049 WO2002067941A2 (en) 2001-02-27 2002-02-26 Combination comprising a signal transduction inhibitor and an epothilone derivative

Publications (1)

Publication Number Publication Date
AT434438T true AT434438T (en) 2009-07-15

Family

ID=26245767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02744903T AT434438T (en) 2001-02-27 2002-02-26 Combination comprising an inhibitor of the signal transduction and an epothilone derivative

Country Status (23)

Country Link
US (1) US7723339B2 (en)
EP (1) EP1385522B1 (en)
JP (1) JP4499359B2 (en)
KR (1) KR100848197B1 (en)
CN (1) CN1511036B (en)
AT (1) AT434438T (en)
AU (1) AU2002308218B2 (en)
BR (1) BR0207649A (en)
CA (1) CA2439268C (en)
CY (1) CY1109347T1 (en)
DE (1) DE60232719D1 (en)
DK (1) DK1385522T3 (en)
ES (1) ES2326264T3 (en)
HK (1) HK1062266A1 (en)
IL (2) IL157466D0 (en)
MX (1) MXPA03007729A (en)
NO (1) NO325416B1 (en)
NZ (1) NZ527764A (en)
PL (1) PL207197B1 (en)
PT (1) PT1385522E (en)
RU (1) RU2313345C2 (en)
SK (1) SK287489B6 (en)
WO (1) WO2002067941A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579351B2 (en) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ Synthesis and intermediates and the like, as well as its use of epothilone
RU2321400C2 (en) 2001-03-14 2008-04-10 Бристол-Маерс Сквибб Компани Epotilone analogue composition in combination with chemotherapeutic agents for cancer treatment
PL368068A1 (en) * 2001-05-16 2005-03-21 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
EP1704863A3 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
JP2005507424A (en) * 2001-10-29 2005-03-17 ノバルティス アクチエンゲゼルシャフト Use of 7H- pyrrolo [2,3-d] pyrimidine derivatives in the treatment of solid tumors
EP1506203B1 (en) 2002-08-23 2007-01-03 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Combinations comprising Epothilones and protein Tyrosine Kinase inhibitors and pharmaceutical uses thereof.
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
AU2006336468B2 (en) 2005-02-11 2012-04-12 University Of Southern California Method of expressing proteins with disulfide bridges
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE4138042C2 (en) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilones, their method of preparation as well as agents containing these compounds
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
PT836605E (en) * 1995-07-06 2002-07-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
AU753546B2 (en) 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
CO4940418A1 (en) * 1997-07-18 2000-07-24 Novartis Ag Crystal modification a N-phenyl-2- pyrimidinamine, processes for their manufacture and use
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
WO2000000485A1 (en) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
EE200100422A (en) * 1999-02-11 2002-12-16 Schering Aktiengesellschaft Epothilone derivatives, their preparation Using jafarmatseutiline
DE19908760A1 (en) * 1999-02-18 2000-08-24 Schering Ag New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators

Also Published As

Publication number Publication date
HK1062266A1 (en) 2010-02-26
RU2313345C2 (en) 2007-12-27
MXPA03007729A (en) 2003-12-04
SK287489B6 (en) 2010-11-08
CA2439268C (en) 2010-01-19
JP2004527493A (en) 2004-09-09
AU2002308218B2 (en) 2005-11-10
US20040132754A1 (en) 2004-07-08
NO20033769L (en) 2003-08-25
BR0207649A (en) 2004-03-09
EP1385522A2 (en) 2004-02-04
EP1385522B1 (en) 2009-06-24
CN1511036B (en) 2010-05-05
ES2326264T3 (en) 2009-10-06
IL157466A (en) 2012-04-30
PT1385522E (en) 2009-09-04
RU2003127392A (en) 2005-03-27
KR20040025900A (en) 2004-03-26
PL363288A1 (en) 2004-11-15
NO325416B1 (en) 2008-04-21
NZ527764A (en) 2006-01-27
WO2002067941A2 (en) 2002-09-06
SK10712003A3 (en) 2004-02-03
KR100848197B1 (en) 2008-07-24
IL157466D0 (en) 2004-03-28
PL207197B1 (en) 2010-11-30
WO2002067941A8 (en) 2003-12-18
DK1385522T3 (en) 2009-10-12
CA2439268A1 (en) 2002-09-06
DE60232719D1 (en) 2009-08-06
US7723339B2 (en) 2010-05-25
WO2002067941A3 (en) 2003-11-20
CY1109347T1 (en) 2014-07-02
NO20033769D0 (en) 2003-08-25
JP4499359B2 (en) 2010-07-07
CN1511036A (en) 2004-07-07

Similar Documents

Publication Publication Date Title
DE60207717D1 (en) Signal component processor
AT285458T (en) Structurally melt adhesives and related procedures
DE60144277D1 (en) Inhibitors of human phosphatidyl-inositol-3-kinase delta
DE60228038D1 (en) Giant magnetoresistive transducer
AT516057T (en) Intravascular platforms and related devices
AT409482T (en) Cathepsincystein protease inhibitors
AT373246T (en) ultrasound transducer
AT254615T (en) C-21 modified epothilones
DE602004017832D1 (en) Display component setting and display component-
DE60032117D1 (en) Fastening element for an orthopedic ring fixator
DE50312980D1 (en) Ftstoffen and flavorings
DE60204553D1 (en) June kinase inhibitors
DE50115561D1 (en) the same spectrophotometer and using
NO20025890D0 (en) Composition for the control of well fluid and gas-engagement and fremgangsmåtefor using the same
NO20025655L (en) Method and device for the determination of reservoir characteristics
AT503483T (en) activity inhibitor of the act
DE60218511D1 (en) Dihydroxypyrimidine carbonsäueramid-inhibitor of the HIV-integrase
DE50200742D1 (en) circuitry
DE60204663D1 (en) Intravascular temperature sensor
DE60207059D1 (en) Drilling and drilling
DE60234125D1 (en) inhibitors e
EE200300351A (en) combination of probiotics
DE60238678D1 (en) Circuit-switched and packet-switched communication
DE60106599D1 (en) phenylacetamides substituted and their use as glucokinase activators
DE60141889D1 (en) Inhibitors of integrin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1385522

Country of ref document: EP